Correlation Between Mineralys Therapeutics, and Ideaya Biosciences

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Ideaya Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Ideaya Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Ideaya Biosciences, you can compare the effects of market volatilities on Mineralys Therapeutics, and Ideaya Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Ideaya Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Ideaya Biosciences.

Diversification Opportunities for Mineralys Therapeutics, and Ideaya Biosciences

0.85

Correlation Coefficient

Mineralys Therapeutics,  Ideaya Biosciences

Very poor diversification

The 3 months correlation between Mineralys and Ideaya is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Ideaya Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ideaya Biosciences and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Ideaya Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ideaya Biosciences has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Ideaya Biosciences go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Ideaya Biosciences

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the Ideaya Biosciences. In addition to that, Mineralys Therapeutics, is 1.63 times more volatile than Ideaya Biosciences. It trades about -0.12 of its total potential returns per unit of risk. Ideaya Biosciences is currently generating about -0.16 per unit of volatility. If you would invest  3,022  in Ideaya Biosciences on October 22, 2024 and sell it today you would lose (804.00) from holding Ideaya Biosciences or give up 26.6% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Ideaya Biosciences

Mineralys Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Ideaya Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ideaya Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Mineralys Therapeutics, and Ideaya Biosciences

The main advantage of trading using opposite Mineralys Therapeutics, and Ideaya Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Ideaya Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ideaya Biosciences will offset losses from the drop in Ideaya Biosciences' long position.

The idea behind Mineralys Therapeutics, Common and Ideaya Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.